GlobalData on MSN7h
Pfizer’s Phase III bladder cancer therapy trial meets primary endpointThe trial showed a 'clinically meaningful' and 'statistically significant' improvement when treated with therapy plus BCG, ...
Zacks.com on MSN5h
Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer StudyData from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain ...
Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.
Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with BCG-naive, high-risk ...
Pfizer’s sasanlimab in combo with BCG improves EFS in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer: New York Monday, January 13, 2025, 13:00 Hrs [IST] ...
U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...
Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.
Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...
The Independent on MSN10h
‘Game changer’ immunotherapy drug could lead to increased survival rates for bladder cancer patientsThe study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...
Patients in the study with advanced bladder cancer had less risk of cancer progressing or returning when treated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback